Streetbeat News

FWBI

First Wave BioPharma Inc

https://www.azurrx.com/

CEO

James Sapirstein

Employees

12

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.

Open

2.93

Mkt cap

6M

Volume

56K

High

3.04

P/E Ratio

-0.06

52-wk high

60.00

Low

2.84

Div yield

N/A

52-wk low

2.33

Roth MKM analyst Jonathan Aschoff has reiterated a 'Buy' rating on First Wave BioPharma (NASDAQ:FWBI) and maintained the price target at $11.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 1:23 pm

During Friday's intraday session, several healthcare stocks experienced significant movements. MSP Recovery (LIFW), Know Labs (KNW), Orchestra BioMed Hldgs (OBIO), Akso Health Group (AHG), Iovance Biotherapeutics (IOVA), and Soleno Therapeutics (SLNO) saw gains, while Avalo Therapeutics (AVTX), PTC Therapeutics (PTCT), First Wave BioPharma (FWBI), Novo Integrated Sciences (NVOS), Ambrx Biopharma (AMAM), and SeaStar Medical Holding (ICU) experienced losses.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 5:31 pm

Several stocks experienced significant price movements in Friday's mid-day session. Novonix Limited's shares rose by 27.4% after the company announced it achieved high-performance battery grade synthetic graphite production milestones. Iovance Biotherapeutics' shares jumped 20.8% after the FDA extended its BLA Priority Review for lifileucel. Faraday Future Intelligent Electric's shares gained 19.5% after announcing a new car delivery. On the other hand, Avalo Therapeutics' shares fell 31.6% after agreeing to divest AVTX-800 series. PTC Therapeutics' shares fell 31.6% after receiving a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna.

Portfolio Pulse from Lisa Levin

September 15, 2023 | 4:40 pm

U.S. stocks traded higher with the Nasdaq Composite gaining more than 100 points. First Wave BioPharma shares spiked 23% after announcing a license agreement for capeserod from Sanofi. PFSweb shares shot up 48% after GXO Logistics announced it will acquire the company. MYT Netherlands Parent B.V. shares gained 13% after reporting Q4 financial results. IBEX Limited shares dropped 25% after reporting worse-than-expected Q4 results and issuing FY24 revenue guidance below estimates. Clearmind Medicine shares were down 57% after announcing pricing of a public offering. BIOLASE shares fell 38% after announcing pricing of a public offering.

Portfolio Pulse from Lisa Levin

September 14, 2023 | 6:30 pm

During Thursday's intraday session, several healthcare stocks experienced significant movements. Gainers included First Wave BioPharma (FWBI), Synlogic (SYBX), ENDRA Life Sciences (NDRA), NeuBase Therapeutics (NBSE), Eloxx Pharmaceuticals (ELOX), and HeartBeam (BEAT). Losers included Biolase (BIOL), TransCode Therapeutics (RNAZ), Bionomics (BNOX), ZyVersa Therapeutics (ZVSA), Harpoon Therapeutics (HARP), and Novo Integrated Sciences (NVOS).

Portfolio Pulse from Benzinga Insights

September 14, 2023 | 5:31 pm

Several stocks experienced significant price movements in Wednesday's mid-day session. First Wave BioPharma shares jumped 89.5% after announcing a license agreement for capeserod from Sanofi. PFSweb gained 48.3% following GXO Logistics' acquisition announcement. Taseko Mines, Avalo Therapeutics, NeuBase Therapeutics, MYT Netherlands Parent, Soluna Holdings, Nikola Corporation, Trinseo, Alaunos Therapeutics, Orchestra BioMed Holdings, Eiger BioPharmaceuticals, Uniti Group, Lixiang Education Holding, TransCode Therapeutics, and Novo Integrated Sciences also saw gains. On the other hand, Sezzle, Clearmind Medicine, BIOLASE, OKYO Pharma, IBEX, Bionomics, MicroCloud Hologram, Harpoon Therapeutics, ZyVersa Therapeutics, Super League Enterprise, Axcella Health, BIMI International Medical, Impel Pharmaceuticals, PureCycle Technologies, Ivanhoe Electric, SIMPPLE, Iovance Biotherapeutics, Radiant Logistics, CS Disco, Ambipar Emergency Response, Genius Sports, and Vital Energy saw declines.

Portfolio Pulse from Lisa Levin

September 14, 2023 | 4:58 pm

U.S. stocks traded higher with the Nasdaq Composite gaining around 100 points. Energy shares jumped by 1.2%. First Wave BioPharma, PFSweb, and MYT Netherlands Parent shares rose significantly after positive news. However, IBEX Limited, Clearmind Medicine, and BIOLASE shares dropped due to negative financial results and public offerings. Oil traded up 1.7% to $90.04.

Portfolio Pulse from Lisa Levin

September 14, 2023 | 4:19 pm

First Wave BioPharma has announced the exercise of warrants and issuance of new warrants in a private placement for $4M, priced at $0.43 per share.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 2:46 pm

US stocks traded higher following the release of PPI data, with the Dow, NASDAQ, and S&P 500 all seeing gains. Energy shares jumped by 1.4%, while consumer discretionary shares fell by 0.1%. US producer prices rose by 0.7% in August 2023, higher than the expected 0.4% increase. Shares of First Wave BioPharma, PFSweb, and TradeUP Acquisition Corp. saw significant increases, while shares of Sezzle, Clearmind Medicine, and BIOLASE fell sharply.

Portfolio Pulse from Lisa Levin

September 14, 2023 | 2:03 pm

During Thursday's pre-market session, several health care stocks experienced significant movement. Gainers included First Wave BioPharma, Avalo Therapeutics, TransCode Therapeutics, Navidea Biopharmaceutical, Longeveron Inc. - Subscription Right, and Evoke Pharma. Losers included Biolase, Bionomics, Scinai Immunotherapeutics, Impel Pharmaceuticals, ZyVersa Therapeutics, and Petros Pharma.

Portfolio Pulse from Benzinga Insights

September 14, 2023 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.